Investor Presentaiton

Actionable information and speed saves patient lives INVESTOR 20 DAY 23 Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer 4x Better patient outcomes with CGP testing 1.00 0.75 Every month delayed in cancer treatment can raise risk of death by around 10%¹ GUARDANT™ OS (probability) 0.50 0.25 + Available testing group + Unavailable testing group Log-rank P<.0001 0 6 12 18 24 30 36 Time (months) ASCO JCO® ascopubs.org/journal/pa Precision Oncology An American Society of Clinical Oncology Journal Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer Chau Aggarwal MD, MPH Melina E. Mamares, MD, MSCE. We-Ting Hwang Pho: Dylan G. Schelee, BS: Tara McWilliams, MS AP Singh, MD: Love Sun MD, MSCE: John Kosteva, MD. Michael F. Castelo, MD: Roger B Cohen MD: Carey J Langer ND Abigail On al Doccetic, MPH Peter N Gabriel, MD, MBE Lawrence N Shulman, MD, FACP Katharine A. Rende, PRO. MSW. MPH, Jettrey C. Thomson MD. Justin E. Sekian, MO, and Erica L Carpe MBA PO 1. Hanna T P, King W D, Thibodeau S, Jalink M, Paulin G A, Harvey-Jones E et al. Mortality due to cancer treatment delay: systematic review and meta-analysis BMJ 2020; 371 :m4087 doi:10.1136/bmj.m4087 2. Aggarwal, Charu et al. "Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer." JCO precision oncology vol. 7 (2023): e2300191. doi:10.1200/PO.23.00191 83

View entire presentation